If you're a member at the warehouse club owned by Walmart, you might find easier access for the blockbuster weight-loss drug that's just gone pill-form.
GLP-1 medications are growing even more accessible, and their mainstream popularity holds steady. Between 2019 and 2024, prescriptions for GLP-1 medications rose nearly 400%, according to a 2025 study from FAIR Health.
Up to now, these appetite- and metabolism-impacting medications had been administered predominantly as an injectable. But this month, pharmaceutical company Novo Nordisk announced the first oral prescription for Wegovy—and Thursday one big-name warehouse club announced an offering of it to its members.
Sam’s Club, the membership-only retail warehouse chain owned by Walmart, announced that beginning the week of January 12, it will offer oral doses of Wegovy in its pharmacies. Wegovy pills will be available in a once-daily 1.5-milligram pill for $149 per month, via Novo Nordisk’s self-pay offer. This contrasts with the 0.25-milligram starter dose of the injectable, according to the dosage schedule on the brand’s site—likely because delivery directly into the blood stream is stronger than through the digestive system.
Pharmacists at the warehouse retailer will also offer guidance, and pharmacy deliveries reportedly will be available.
Taylor Kravatz, PharmD, pharmacy manager at Sam’s Club, told The Healthy: “When patients start GLP-1 medications, one of the first questions we hear is about side effects, particularly stomach-related issues.” Dr. Kravatz added: “As pharmacists, our goal is to help patients feel prepared and supported by setting clear expectations and sharing practical guidance—such as starting with smaller, high-protein meals, understanding what to watch for as doses change, reviewing medication-safety considerations alongside other prescriptions, and knowing when to reach out to us or their physician with questions.”
Wegovy is a brand name for semaglutide, a type of GLP-1 receptor agonist medication that is used to help lower blood sugar alongside diet and exercise for those who have type 2 diabetes, as well as lower the risk of heart attack, stroke, obesity, and heart and blood vessel disease, according to the Mayo Clinic. The Novo Nordisk January announcement stated that a three-phase clinical trial on the pill, involving 307 participants over a 16-month period, led to a 16.6% loss in body weight, compared to a 2.7% reduction among the control group.
While other medications that include semaglutide, like Ozempic, are approved specifically for type 2 diabetes management, Wegovy is approved by the U.S. Food and Drug Administration (FDA) to help adults with obesity or excess weight lose and keep weight off, as well as lower the risk of heart attack, stroke, or death for overweight or obese adults with a history of heart disease.
Speak with your doctor before changing your diet or starting a new medication.
For daily wellness updates, subscribe to The Healthy newsletter and follow The Healthy on Facebook and Instagram. Keep reading:
